Diarrheal disease
Therapeutic area
Gastroenterology
Rare disease
No
- Definition
- The condition of having at least three loose or liquid bowel movements each day.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diarrheal disease
- Therapeutic area
- Gastroenterology
- diarrheal disease
- diarrhea
- diarrheal disease
- diarrheal disorder
- diarrhoea
- frequent stools
- loose stools
- diarrhoea of presumed infectious origin
- All therapeutic areas
- Gastroenterology
- Severity
- Mild
- MONDO ID
- MONDO:0001673
- Parent condition
- MONDO:0004335
Related records
Broader conditions (4)
- Digestive system disorder
- Disease
- Disease by body system or component
- Human disease
Narrower conditions (34)
- Acute diarrhea
- Amebic dysentery
- Chronic diarrhea due to glucoamylase deficiency
- Chronic diarrheal disease
- Congenital diarrhea
- Congenital diarrhea 5 with tufting enteropathy
- Congenital diarrhea 6
- Congenital diarrhea 7 with exudative enteropathy
- Congenital malabsorptive diarrhea 4
- Congenital secretory chloride diarrhea 1
- Congenital secretory diarrhea
- Congenital secretory sodium diarrhea 3
- Congenital secretory sodium diarrhea 8
- Congenital sodium diarrhea
- Diarrhea 10, protein-losing enteropathy type
- Diarrhea 11, malabsorptive, congenital
- Diarrhea 12, with microvillus atrophy
- Diarrhea 13
- Diarrhea 14, congenital
- Diarrhea 15, congenital
Trials (709)
- "Alcohol Based Hand Sanitizers for the Prevention of Acute Diarrheal Disease and Acute Respiratory Infection in Children Under 5 Attending Childcare Centers in Bogotá, Cundinamarca and Tolima, in Colombia: a Cluster Randomized Control Trial"
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
- 64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings
- A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
- A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
- A Clinical Trial to Evaluate the Effects of a Fibre Supplement on Microbiome and Gut Health
- A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
- A Comparison of Three Medications to Treat Diarrhea in Adults.
- A Controlled Trial of Plantain Powder in Infantile Diarrhea
- A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients
- A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)
- A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
- A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
- A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients
- A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea
- A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
- A Novel Iron Supplement for Athletes: Phase I
Approved drugs (10)
- Bismuth subsalicylate
- Crofelemer
- Eluxadoline
- Fidaxomicin
- Loperamide hydrochloride
- Nitazoxanide
- Rifamycin sodium
- Rifaximin
- Telotristat etiprate
- Vancomycin
Drugs in development (42)
- Actoxumab Phase 3
- Amoxicillin Early phase 1
- Amylase (pancrelipase) Phase 3
- Azithromycin Phase 3
- Bifidobacterium SPP. Phase 2
- Budesonide Phase 2
- Calcium carbonate Phase 3
- Ciprofloxacin Phase 3
- Clavulanic acid Early phase 1
- Diethylhomospermine Phase 1
- Elsiglutide Phase 2
- Glutamine Phase 3
- Glycine Phase 3
- IOWH-032 Phase 2
- Irinotecan hydrochloride Phase 3
- Lactobacillus acidophilus Phase 2
- Lactoferrin, bovine Phase 2
- Lactose, anhydrous Phase 3
- Lagatide Phase 2
- Lamivudine Phase 3
Other linked drugs (5)
- Cholestyramine
- CO-trimoxazole
- Diphenoxylate
- Furazolidone
- Ramosetron hydrochloride